Skip to main content
padlock icon - secure page this page is secure

In Silico and Biochemical Analyses Identify Quinone Reductase 2 as a Target of Piceatannol

Buy Article:

$63.00 + tax (Refund Policy)

To obtain information on anti-prostate cancer (CaP) activities of piceatannol, a metabolite biotransformed from resveratrol by cytochrome P450 CYP1B, CWR22Rv1 cells were incubated with increasing dose of piceatannol. Proliferation and apoptosis assays in exposed cells showed that piceatannol produced inhibition comparable to resveratrol. To determine whether quinone reductase 2 (NQO2) plays a role in the observed effects, in silico analysis was performed. Piceatannol interacted with NQO2 at the same site as resveratrol forming hydrogen bond with asparagine-161 (ASN161). NQO2 mediated anti-CaP effects of piceatannol were also tested and supported by the attenuation of anti-proliferative activity and reduction in extent of inhibition of NQO2 activity by piceatannol in NQO2-knockdown cells relative to NQO2- expressing cells, and by the copious expression of CYP1B in CWR22Rv1 cells. These results show that NQO2 is an intracellular target for piceatannol, suggesting that CaP prevention by resveratrol may be partially attributed to its conversion to piceatannol.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CWR22Rv1 prostate cancer cells; NQO2; NQO2 knockdown; Resveratrol; biotransformation; chemoprevention; cytochrome P450 CYP1B1; in silico analysis; piceatannol

Document Type: Research Article

Publication date: 01 November 2013

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more